ONE Bio Corp
ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE business unit engages in the development, manufacture, and commercialization of bio-ec… Read more
ONE Bio Corp (ONBI) - Net Assets
Latest net assets as of September 2011: $49.29 Million USD
Based on the latest financial reports, ONE Bio Corp (ONBI) has net assets worth $49.29 Million USD as of September 2011.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($82.86 Million) and total liabilities ($33.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $49.29 Million |
| % of Total Assets | 59.48% |
| Annual Growth Rate | 310.22% |
| 5-Year Change | 122319.36% |
| 10-Year Change | N/A |
| Growth Volatility | 82.33 |
ONE Bio Corp - Net Assets Trend (2005–2010)
This chart illustrates how ONE Bio Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONE Bio Corp (2005–2010)
The table below shows the annual net assets of ONE Bio Corp from 2005 to 2010.
| Year | Net Assets | Change |
|---|---|---|
| 2010-12-31 | $42.59 Million | +28.74% |
| 2009-12-31 | $33.08 Million | +126978.59% |
| 2008-12-31 | $-26.07K | -141.33% |
| 2007-12-31 | $63.09K | +81.33% |
| 2006-12-31 | $34.79K | -5.20% |
| 2005-12-31 | $36.70K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ONE Bio Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 61336.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2010)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $17.06 Million | 40.53% |
| Common Stock | $6.70K | 0.02% |
| Other Comprehensive Income | $4.86 Million | 11.56% |
| Other Components | $20.16 Million | 47.90% |
| Total Equity | $42.09 Million | 100.00% |
ONE Bio Corp Competitors by Market Cap
The table below lists competitors of ONE Bio Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Boussard and Gavaudan Holding Ltd ORD
LSE:BGHS
|
$27.61 |
|
Conferize A/S
CO:CONFRZ
|
$27.65 |
|
TripSitter Clinic Ltd.
PINK:TSTTF
|
$27.73 |
|
SUNU ASSURANCES NIGERIA PLC
XNSA:SUNUASSUR
|
$27.97 |
|
American Graphite Technologies Inc
PINK:AGIN
|
$27.48 |
|
US Solar Fund PLC
LSE:USFP
|
$27.33 |
|
TRIPPLE GEE AND COMPANY PLC
XNSA:TRIPPLEG
|
$27.14 |
|
TANTALIZERS PLC
XNSA:TANTALIZER
|
$27.09 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONE Bio Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2009 to 2010, total equity changed from 29,428,563 to 42,093,847, a change of 12,665,284 (43.0%).
- Net income of 8,676,612 contributed positively to equity growth.
- Share repurchases of 80,000 reduced equity.
- Other comprehensive income increased equity by 3,368,140.
- Other factors increased equity by 700,532.
Equity Change Factors (2009 to 2010)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.68 Million | +20.61% |
| Share Repurchases | $80.00K | -0.19% |
| Other Comprehensive Income | $3.37 Million | +8.0% |
| Other Changes | $700.53K | +1.66% |
| Total Change | $- | 43.04% |
Book Value vs Market Value Analysis
This analysis compares ONE Bio Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.73 | $0.00 | x |
| 2006-12-31 | $0.52 | $0.00 | x |
| 2007-12-31 | $0.02 | $0.00 | x |
| 2008-12-31 | $-0.01 | $0.00 | x |
| 2009-12-31 | $5.75 | $0.00 | x |
| 2010-12-31 | $6.55 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ONE Bio Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.61%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.59%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.66x
- Recent ROE (20.61%) is below the historical average (22.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 47.27% | 10.59% | 1.93x | 2.31x | $13.68K |
| 2006 | -10.89% | -1.83% | 1.69x | 3.52x | $-7.27K |
| 2007 | 59.06% | 6.44% | 2.97x | 3.08x | $30.95K |
| 2008 | 0.00% | -53.85% | 1.54x | 0.00x | $-39.53K |
| 2009 | 16.22% | 21.62% | 0.40x | 1.86x | $1.83 Million |
| 2010 | 20.61% | 16.59% | 0.75x | 1.66x | $4.47 Million |
Industry Comparison
This section compares ONE Bio Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONE Bio Corp (ONBI) | $49.29 Million | 47.27% | 0.68x | $27.49 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |